Medicus Pharma submits ODD application to U.S. FDA for SkinJect

Medicus Pharma (MDCX) announced the submission of an Orphan Drug Designation, ODD, application to the U.S. Food and Drug Administration for SkinJect, D-MNA, for the treatment of basal cell carcinoma, BCC, in patients with Gorlin Syndrome, a rare genetic disorder characterized by the development of multiple, recurrent skin cancers. The submission represents a strategic expansion of the SkinJect program into a high unmet need orphan indication, where current treatment options are limited and often involve repeated surgical procedures associated with cumulative morbidity and disfigurement.